Travelzoo (TZOO) – Investment Quarter Masks Long-Term Value


Wednesday, July 29, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Accelerated membership investment weighed heavily on Q2 results. Revenue declined 3% to $23.2 million, while Travelzoo reported a $2.8 million operating loss and a non-GAAP operating loss of $2.1 million. The decline reflected geopolitical uncertainty across Travelzoo’s markets and a deliberate increase in member-acquisition spending.

The recurring-revenue strategy is gaining measurable traction. Membership and subscription revenue increased to approximately $5.0 million in Q2 from $3.0 million in the prior-year period, while deferred revenue rose 54% from year-end to $13.4 million. Membership renewals reached a record level.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

GeoVax Labs (GOVX) – GeoVax Reports 2Q26 With Clinical Study Plans Moving Forward


Wednesday, July 29, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

GeoVax Reported 2Q26 With Updates For GEO-MVA and Oncology Programs. GeoVax reported a 2Q26 net loss of $4.4 million or $(0.97) per share, lower than our expected loss of $5.8 million. R&D expenses were lower than we projected due to strategic changes, with priority given to preparations for the upcoming Phase 3 trial of GEO-MVA in MPox and the Phase 2 trial of Gedeptin in oncology. Cash on June 30, 2026 was approximately $3.1 million.

Strategic Changes Lowered The 2Q26 Loss. As discussed in our Research Note on May 27, GeoVax will focus on GEO-MVA in infectious diseases and Gedeptin in oncology. These programs have established regulatory pathways, patient needs, and market potential.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

The Machine That Builds Every Advanced Chip Just Got Some Competition

Shares of ASML Holding, the Dutch company that has held a near-monopoly on the machines used to manufacture the world’s most advanced semiconductors, fell 5.8% Monday after a report from The Information cited sources familiar with the matter saying China is developing its own deep ultraviolet lithography machines. Other chipmakers dipped on the news before paring some of the losses later in the session, part of a broader mixed trading day in which the Dow closed higher while technology and energy stocks lagged behind gains in consumer staples and consumer discretionary names, a pattern consistent with the rotation away from crowded AI-adjacent positions that has been building for weeks.

The significance of the ASML report is difficult to overstate for anyone tracking global technology supply chains. Lithography machines are the single most critical piece of equipment in semiconductor manufacturing, using precisely controlled light to etch circuit patterns onto silicon wafers at scales measured in nanometers. ASML is the only company in the world capable of producing the most advanced version of this equipment, extreme ultraviolet lithography systems, giving it an effective monopoly over the tools required to manufacture cutting-edge chips.

Why This Matters Beyond One Stock

Deep ultraviolet lithography, while a step below the most advanced extreme ultraviolet systems, is still essential equipment for manufacturing a wide range of semiconductors, including chips used in automotive, industrial, and mid-tier computing applications. US and allied export restrictions have blocked China from accessing ASML’s most advanced tools for years, part of a broader effort to slow Chinese progress in cutting-edge chip manufacturing. If China has made genuine progress developing its own DUV capability domestically, it represents a meaningful step toward reducing that dependency, even if true extreme ultraviolet capability remains years away.

A Sector Already on Edge

This report did not land in a vacuum. Chip stocks have been under sustained pressure for weeks as investors grow increasingly skeptical about the pace and sustainability of AI-related capital expenditure, a concern that deepened after last week’s earnings from Tesla and Alphabet confirmed both companies are continuing to spend heavily on AI infrastructure. Markets are also bracing for the Federal Reserve’s policy decision this week, with traders now pricing in at least a modest probability of a rate move as early as this meeting. Investors are still awaiting quarterly guidance this week from Microsoft, Amazon, Apple, and Meta, each expected to offer further detail on AI infrastructure spending across the industry.

Against that backdrop, the ASML supply chain story adds an entirely new dimension of uncertainty. It is no longer just a question of whether AI infrastructure spending will pay off, or whether the Fed holds steady. It is now also a question of whether the equipment monopoly underpinning the entire global chip manufacturing hierarchy is beginning to erode.

What It Means for Smaller Semiconductor Companies

For investors tracking companies below the $2 billion market cap threshold in the semiconductor equipment, materials, and components space, this development is worth watching closely rather than reacting to immediately. A genuine shift in China’s domestic manufacturing capability would reshape global supply chains over years, not days, and smaller companies supplying specialized components, materials, or services into either the established ASML-centric supply chain or an emerging China-based alternative could see their competitive positioning shift meaningfully depending on how this plays out.

The semiconductor equipment monopoly that has underpinned global chip manufacturing for over a decade just showed its first real crack. Whether that crack widens into something structural, or turns out to be an overstated report, will be one of the more important supply chain stories to track through the rest of this year.

Bitcoin Falls to $63,000 as Fed Decision Looms and Crypto’s Landmark Legislation Loses Momentum

Bitcoin dropped more than 2% Tuesday to trade just above $63,000, its lowest level in ten days, as three separate pressures converged on the world’s largest cryptocurrency at once. A broader rout in AI-related chip stocks has weighed on risk sentiment across markets. Ambiguity ahead of the Federal Reserve’s policy decision Wednesday has kept traders cautious. And momentum behind crypto’s most significant pending legislation in Congress appears to be fading just as a key deadline approaches.

Bitcoin is now down roughly 50% from its October all-time high near $126,000, a decline that has stretched across nearly the entire crypto market and weighed heavily on companies that built treasury strategies around holding the token.

The Clarity Act Deadline Is Closing In

The most immediate concern is legislative. The Clarity Act, which would establish a federal legal framework covering market oversight, institutional participation guidelines, and consumer and business protections across much of the crypto industry, has been widely viewed as the most consequential piece of crypto legislation moving through Congress this year. That optimism has faded in recent days as the bill’s timeline runs up against Congress’s August recess, which begins after next week.

Prediction markets have registered the shift directly. Odds that the bill becomes law this year have fallen to 35%, down sharply from 55% earlier this month. Without a clear regulatory framework in place, institutional investors who have been waiting on the sidelines for legal clarity have less reason to commit fresh capital, removing a demand catalyst that many market participants had been counting on for the second half of the year.

Why the Fed Meeting Matters More Than the Decision Itself

The Federal Reserve’s policy decision Wednesday is the second major pressure point. Markets widely expect the Fed to hold rates steady, but for crypto specifically, the messaging around financial conditions and inflation matters more than the decision itself. Traders have increasingly priced in the possibility of a rate hike over the past several trading sessions, and while a hawkish hold remains the most likely outcome, the market cannot fully rule out a hike given the current inflation backdrop.

Crypto assets, which carry no yield and derive much of their valuation from liquidity conditions and risk appetite, are especially sensitive to shifts in the rate outlook. A Fed that signals persistent inflation concern or leaves the door open to further tightening removes exactly the kind of liquidity support that has historically fueled bitcoin rallies.

A Seasonally Weak Stretch Ahead

Compounding both pressures, August and September have historically been bitcoin’s seasonally weakest months as trading liquidity typically thins heading into the fall. Analysts covering the space have identified strong technical support near $55,000 and suggested they would be buyers if the Clarity Act fails to pass and bitcoin sells off to that level, framing the current environment as one where downside risk is elevated but not necessarily unlimited.

What It Means for Crypto-Exposed Small Caps

For investors tracking publicly traded companies with direct bitcoin exposure, this convergence of pressures is a live risk factor rather than an abstract one. Bitcoin miners and companies that adopted bitcoin treasury strategies see their equity value move in near lockstep with the token’s price, and a sustained decline toward the $55,000 support level would compress mining economics and pressure balance sheets that are already sensitive to energy costs and financing terms.

The path forward depends on the resolution of two distinct catalysts arriving almost simultaneously: whether the Fed’s messaging Wednesday leans hawkish or dovish, and whether the Clarity Act can find a path through Congress before lawmakers leave for August recess. Until both are resolved, crypto and the companies tied to it are likely to remain caught between regulatory uncertainty and monetary policy risk at the same time.

Perfect (PERF) – Fundamentals Overshadowed by Pending Buyout


Tuesday, July 28, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Another quarter of improving profitability. Revenue remained stable while higher gross margins and disciplined expense management drove another quarter of improving earnings quality.

AI SaaS model continues to scale. Gross margins remained above 80%, demonstrating the attractive economics of the company’s subscription-driven AI platform and expanding operating leverage.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

First Phosphate Corp. (FRSPF) – Gaining Momentum


Tuesday, July 28, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Building North America’s LFP Supply Chain. First Phosphate Corp. is a Québec-based critical minerals development company focused on establishing a fully integrated North American lithium iron phosphate (LFP) battery materials supply chain. First Phosphate is dedicated exclusively to supplying the rapidly expanding LFP battery market through the production of high-purity igneous phosphate, purified phosphoric acid, and iron phosphate precursor materials.

Differentiated with Significant Competitive Advantages. First Phosphate benefits from significant competitive advantages and differentiation within both the phosphate industry and the broader critical minerals sector. Most phosphate producers worldwide focus on fertilizer markets using sedimentary phosphate deposits that require significant upgrading and are generally less suitable for producing battery-grade phosphoric acid. By contrast, First Phosphate is exclusively targeting the LFP battery industry using rare high-purity igneous phosphate, allowing it to focus on higher-value specialty battery materials.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Beasley Broadcast Group (BBGI) – Building a More Resilient Local Media Platform


Tuesday, July 28, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Executing a multi-year turnaround strategy. Management is focused on three strategic priorities: stabilizing local direct advertising, expanding higher-margin owned-and-operated digital products, and strengthening the balance sheet through disciplined deleveraging. We believe successful execution could materially improve the company’s earnings profile over the next several years.

Digital mix continues to improve. Digital revenue represented more than 25% of total company revenue during the first quarter of 2026, while owned-and-operated digital products increased to approximately 65% of digital revenue. We believe the improving revenue mix should support higher margins, stronger customer retention, and improved free cash flow generation over time.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Alliance Resource Partners (ARLP) – Second Quarter 2026 Review and Outlook


Tuesday, July 28, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Second Quarter Financial Results. Compared to the prior year period, second-quarter 2026 revenue increased to $551.6 million from $547.5 million due to strong oil & gas royalty revenues, increased coal sales volumes, and higher other revenues, partially offset by a lower average realized coal sales price per ton. Adjusted EBITDA increased 14.7% to $185.7 million compared to $161.9 million in the second quarter of last year. Adjusted net income attributable to ARLP increased to $79.6 million, or $0.61 per unit, compared to $59.4 million, or $0.46 per unit, during the prior year period. Second quarter financial results were largely in line with our estimates. We had projected total revenue of $553.5 million, adj. EBITDA of $181.2 million, and EPU of $0.62.

Oil & Gas Royalties Remain a Key Growth Driver. The oil & gas royalties segment delivered record quarterly revenue and segment adjusted EBITDA, driven by increased volumes and higher commodity prices. On July 1, ARLP closed the $206.2 million AllDale III and IV acquisition. Crude oil volumes are now expected to be in the range of 1.95 million to 2.05 million barrels, natural gas volumes are expected to be in the range of 10.0 million to 10.5 million MCF, and liquids volumes are expected to be in the range of 1.1 million to 1.2 million barrels.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Apple Passed Nvidia as the World’s Most Valuable Company. Spending Less on AI Just Became a Winning Strategy

Apple reclaimed the title of the world’s most valuable public company Monday, overtaking Nvidia as its stock pushed toward a record high close. Apple’s market capitalization reached approximately $4.94 trillion, edging past Nvidia’s $4.83 trillion. The shift caps a remarkable turnaround for a company that spent much of the past two years being criticized for lagging behind its peers on artificial intelligence investment.

Apple shares have climbed more than 22% year to date, outperforming every other member of the so-called Magnificent Seven. The reason is almost the inverse of what drove the group’s dominance over the past two years. Investors are increasingly rewarding Apple precisely because it has not spent aggressively on AI infrastructure, treating capital discipline as a genuine strength rather than a competitive weakness.

The Capex Divide Reshaping Big Tech

Data tracked through Yahoo Finance’s AlphaSpace shows Apple’s capital expenditures have actually declined over the past three quarters, a striking contrast to nearly every other major technology company racing to build AI infrastructure. That restraint stands in sharp relief against Alphabet, which raised its capital spending outlook last week to fund its AI infrastructure buildout, and Tesla, which increased spending to support its robotaxi and robotics ambitions. Shares of both companies fell following their respective earnings reports. Alphabet is up only about 3% year to date, and Tesla has tumbled roughly 30% over the same period.

The market’s message has become increasingly clear this earnings season. Companies spending aggressively on AI capacity are being asked hard questions about return on that investment, while companies demonstrating they can capture AI-driven demand without ballooning capital expenditures are being rewarded with premium valuations.

A Pivotal Week Ahead

Apple reports earnings Thursday after the closing bell, and the report carries added significance beyond the usual quarterly scrutiny. Investors will be watching closely for signs the company can scale its Apple Intelligence features across its device lineup without a meaningful increase in capital expenditures or pressure on operating margins. If Apple can demonstrate that its AI strategy works within its existing capital-light framework, it would validate the market’s current thesis in dramatic fashion.

The timing carries additional weight. Thursday will mark Tim Cook’s final earnings call as CEO before he steps down September 1 to become executive chairman, with John Ternus, a longtime hardware engineering veteran at Apple, taking over as chief executive. Microsoft, Amazon, and Meta all report later this week as well, and all three are expected to announce further increases in AI-related spending, setting up a direct contrast with Apple’s approach in real time.

What This Means for the Broader Market

For investors tracking the AI infrastructure ecosystem, the leadership change at the top of the market matters beyond Apple and Nvidia individually. It reinforces a theme that has run through this entire earnings season: the market is no longer rewarding AI spending simply because it is AI spending. It is scrutinizing whether that capital is translating into visible product outcomes and sustainable margins.

That distinction has real implications down the market cap spectrum. Smaller companies supplying components, software, and infrastructure into the AI buildout are increasingly being evaluated on the same terms, whether their growth is funded responsibly or whether it depends on the kind of unchecked capital expenditure that has weighed on stocks like Alphabet and Tesla this earnings season. Apple’s ascent back to the top is, in part, the market rewarding exactly the kind of capital discipline that investors are now demanding across the board.

argenx Pays an 86% Premium for Forte Biosciences. What Made a Clinical-Stage Biotech Worth $2.2 Billion

argenx (Euronext & Nasdaq: ARGX) announced Monday it has entered into a definitive agreement to acquire Forte Biosciences (Nasdaq: FBRX) for $77 per share in cash, a total equity value of approximately $2.2 billion. The price represents an 86% premium to Forte’s volume-weighted average trading price since July 9, when the company reported positive Phase 1b data in vitiligo. That is an unusually large premium even by the standards of this year’s active biotech M&A market, and it reflects just how quickly clinical data can transform a small cap company’s valuation.

The transaction is structured as a cash tender offer funded entirely from argenx’s existing cash on hand, with no financing condition attached. Closing is expected in the third quarter of 2026, subject to a majority of Forte shares being tendered and clearance under the Hart-Scott-Rodino Antitrust Improvements Act.

From Strategic Investor to Full Acquirer

This deal did not appear out of nowhere. argenx had already made a strategic investment in Forte Biosciences prior to this announcement, giving it an early window into the company’s clinical progress before committing to a full buyout. That structure, investing first and acquiring later once the data supports it, reflects a disciplined approach that reduces risk for the acquirer while still preserving the option to move quickly once a program proves itself out.

The proof came fast. Forte’s lead asset, FB102, is a first-in-class anti-CD122 antibody that recently delivered statistically significant Phase 1b results in vitiligo, following earlier positive Phase 1b data in celiac disease reported last year, with Phase 2 celiac data expected in the second half of 2026. Those clinical readouts were the direct trigger for argenx’s decision to convert its strategic stake into a full acquisition.

Why CD122 Biology Matters

FB102’s mechanism targets pathogenic T-cell and NK-cell activity through CD122 biology, a distinct approach from the antibody mechanisms already in argenx’s portfolio, which includes efgartigimod, empasiprubart, adimanebart, and ARGX-121. Rather than duplicating existing capability, the acquisition broadens argenx’s ability to address autoimmune disease through an entirely different dimension of immune system dysfunction.

The commercial upside extends well beyond vitiligo and celiac disease. Management described FB102 as having pipeline-in-a-product potential, meaning the same molecule could eventually address multiple autoimmune conditions including alopecia areata, each representing a separate commercial opportunity from a single clinical asset. That kind of multi-indication potential is precisely what allows a clinical-stage company with no approved products to command a multibillion-dollar acquisition price.

What It Signals for Small Cap Biotech Investors

For investors tracking clinical-stage companies in the small and microcap immunology and autoimmune disease space, the Forte transaction reinforces a pattern that has defined biotech M&A throughout 2026. Large, well-capitalized immunology and oncology platforms are increasingly using strategic minority investments as a low-risk way to monitor promising early-stage science, then moving decisively to full acquisitions once clinical data de-risks the program. Statistically significant Phase 1b results, even well ahead of any approval pathway, are proving sufficient to justify premiums approaching 90% over recent trading prices.

That dynamic matters for the broader small cap biotech landscape. Companies advancing differentiated mechanisms in autoimmune disease, a therapeutic area with persistent unmet need and limited recent innovation, are demonstrating that credible early clinical validation can translate into outsized valuation outcomes well before a drug ever reaches the market. The Forte deal is the latest evidence that the current biotech M&A cycle rewards genuine scientific differentiation over scale.

BlackRock Is Selling $12.3 Billion in Bonds to Fund a Meta Data Center. Wall Street Is Watching to See Who Buys

The debt-financed AI buildout just got its next major test. BlackRock began marketing $12.3 billion in high-grade bonds Friday to fund a massive data center campus in El Paso, Texas, built to power Meta Platforms’ artificial intelligence workloads. The offering is being sold through a single tranche of notes due in 2048, with price talk at approximately 2.875 percentage points over Treasuries. JPMorgan Chase and Morgan Stanley are running the offering.

The financing structure is worth understanding. The project is owned through a holding company tied to BlackRock, with BlackRock subsidiaries Global Infrastructure Management and HPS Investment Partners holding an 80% stake and Meta owning the remaining 20%. Once complete, the facility is expected to provide as much as 1 gigawatt of computing capacity dedicated to AI workloads, enough to power hundreds of thousands of homes if it were serving the grid instead of server racks.

Why This Deal Matters Beyond Its Size

At $12.3 billion, this is one of the largest single data center bond offerings to reach the market this year, and the timing makes it a genuine test of investor appetite. The offering arrives just days after Oracle’s stock fell more than 50% from its June high on concerns about debt-funded AI infrastructure spending and customer concentration risk tied to its own data center buildout. It also follows Alphabet shares falling after the company disclosed a $205 billion spending plan that fueled fresh investor anxiety about the pace and sustainability of AI capital expenditure across the industry.

Against that backdrop, BlackRock’s bond sale is effectively asking bond investors a direct question: is the market still willing to underwrite massive, long-duration AI infrastructure debt at reasonable spreads, or has sentiment shifted enough that these deals now require a real risk premium to get done. A note due in 2048 is a 22-year commitment, and how tightly or loosely it prices will say a great deal about whether fixed income investors share the equity market’s growing skepticism about AI capex, or whether they view infrastructure-backed debt with a hyperscaler tenant as a fundamentally different risk than a company’s own balance sheet leverage.

The Structural Shift Toward Off-Balance-Sheet AI Financing

This deal also reflects a broader trend worth watching. Rather than funding data centers directly on their own balance sheets the way Oracle largely has, companies like Meta are increasingly structuring these projects through joint ventures with infrastructure investors like BlackRock, keeping the debt at arm’s length while still securing the compute capacity they need. That structure spreads the financial risk of the AI buildout across a wider pool of infrastructure capital rather than concentrating it entirely on the tech company’s own credit.

What It Means for Smaller Companies

For investors tracking the broader AI infrastructure ecosystem, this offering is a useful barometer independent of Meta or BlackRock specifically. If a $12.3 billion, investment-grade-rated data center bond prices well, it signals that credit markets still have confidence in the underlying demand for AI compute, which supports continued capital flowing to the smaller companies supplying power infrastructure, cooling systems, and specialized components into projects exactly like this one. If it prices poorly or gets downsized, it would be an early signal that the capital markets are beginning to price AI infrastructure risk more conservatively across the board, a dynamic that would eventually reach every tier of the supply chain, including the smallest companies in it.

SelectQuote (SLQT) – Q4 Preview—Building Toward a Cash Flow Inflection


Friday, July 24, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q4 Should Reinforce Improving Cash Flow Story. Although fourth quarter revenue should normalize following the seasonally strong Medicare enrollment period, we expect another quarter of healthy profitability and cash generation that reinforces management’s expectation for a significant cash flow acceleration entering fiscal 2027.

Senior Business Demonstrates Structural Earnings Strength. Even amid continued Medicare Advantage disruption, the Senior business has consistently produced EBITDA margins above 25% during enrollment periods. We expect another solid quarter as disciplined marketing spend and strong customer retention continue to support attractive economics.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Resources Connection (RGP) – Reports 4Q26 Results In-line with Expectations


Friday, July 24, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. Resources Connection’s 4Q26 results were mostly in line with management expectations. Overall industry conditions were consistent with 3Q26, suggesting the market is stabilizing. During the quarter, RGP continued to make focused investments to support future growth, which we are hopeful will occur in 2HFY27.

4Q26 Details. Revenue of $106.1 million was down 18.3% on a constant currency basis y-o-y but was within management’s $104-$109 guide. 4Q26 also had one less week of billable activity compared to 4Q25. Gross margin of 37.6% was down from 40.2% y-o-y but exceeded the top end of management’s guide. Adjusted EPS was a net loss of $0.07 compared to EPS of $0.16 in 4Q25.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.